MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies _ Alzheimers & Dementia
Sio Gene Therapies, Inc. (NASDAQ: SIOX)_formerly, Axovant Gene Therapies Ltd (AXGT), formerly, Axovant Sciences (AXON)
Organization & Developments: Axovant
Parents
Sio Gene Therapies, Inc. (NASDAQ: SIOX)_formerly, Axovant Gene Therapies Ltd (AXGT), formerly, Axovant Sciences (AXON)
Children
2018: Axovant Neuro Drug Stumbles and Falls in Phase 2, Shares Drop 50%_xconomy
2018: Axovant Sciences: 5 Trials, 4 Failures - Expect A Fifth - Axovant Sciences (NASDAQ:AXON)
2018: Axovant Tumbles On Failed Drug, But Was Never Part Of The Game Plan_seekingalpha.com
2018: Axovant's Latest Data Is The Nail In The Coffin - Axovant Sciences (NASDAQ:AXON)
2019: A Potential Catalyst Trade Presents On Axovant _ seekingalpha.com
2019: Biotech Analysis Central Preview Series: Axovant Sciences_seekingalpha.com
2019: Three Q4'19 Catalysts For Axovantseekingalpha.com
2020: Axovant seeks to forget the past as the company rebrands to Sio Gene Therapies
2021: Sio Gene Therapies: A Speculative Buy For Their Undervalued Gene Therapies
2021: Sio Gene Therapies: Risk-On Gene Therapy Prospect May Offer Value For Money
2022: Sio Gene Therapies warns of 'significant' layoffs after ditching final two assets
2024: Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share
Jumps
*Key People: Axovant
Finance & Acquisitions: Axovant